<div id="readability-page-1">ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) is one of the stocks that will double in 2026. On December 8, Wells Fargo raised the firm’s price target on Oric Pharmaceuticals to $25 from $19 and maintained an Overweight rating on the shares. Although enozertinib has previously been overshadowed by ORIC-944, the intriguing data presented at ESMO Asia is […]</div>

ORIC

<p>富國銀行將 ORIC Pharmaceuticals 的目標股價從 19 美元上調至 25 美元，並維持 “增持” 評級，原因是 Enozertinib 在 ESMO Asia 的數據表現令人鼓舞</p>

由於 Enozertinib 在 ESMO 亞洲會議上發佈了引人注目的數據，ORIC Pharmaceuticals（ORIC）股價飆升，促使富國銀行提高了其估值